William Garvis, MD
Otology & Neurotology · Minneapolis, MNNPI 1780686584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Intersect ENT, Inc. at 35.7% of the total.
Across 13 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$117
- Hologic Sales And Service, LLC$47
- Optinose US, Inc.$47
- Cochlear Americas$34
- Novartis$23
- Merck$23
- plus $37 from 2 others
What the payments were for
- Food & beverage$327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 3 | $117 |
| Hologic Sales And Service, LLC | 2 | $47 |
| Optinose US, Inc. | 3 | $47 |
| Cochlear Americas | 1 | $34 |
| Novartis | 1 | $23 |
| Merck | 1 | $23 |
| Aerin Medical Inc. | 1 | $20 |
| GSK | 1 | $17 |
How this compares
Too few otology & neurotology providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 35 | $5,158 |
| Ofloxacin | 44 | $1,244 |
| Ipratropium Bromide | 24 | $816 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 80 | $734 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 16 | $224 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 39 | $222 |
| Meclizine Hcl | 19 | $205 |
| Methylprednisolone | 19 | $141 |
Paid to pharmacies, not to this prescriber.
Other otology & neurotology in Minneapolis
- Margaret EngelhardtMinneapolis$3K
- Tina HuangMinneapolis$1K
- Neil PatelRochester$41K
- John MarinelliRochester$3K
- Madison EppersonRochester$2K
- John MecciaWaconia$198
- John LarsenWaconia$37
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.